179 related articles for article (PubMed ID: 37833648)
41. Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients from Southern Sri Lanka: An Echocardiographic Analysis.
Sandamali JAN; Hewawasam RP; Fernando MACSS; Jayatilaka KAPW; Madurawe RD; Sathananthan PP; Ekanayake U; Horadugoda J
Biomed Res Int; 2020; 2020():1847159. PubMed ID: 33274195
[TBL] [Abstract][Full Text] [Related]
42. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
Sánchez-Medina J; Gonzalez-Ramella O; Gallegos-Castorena S
J Pediatr Hematol Oncol; 2010 May; 32(4):294-7. PubMed ID: 20404753
[TBL] [Abstract][Full Text] [Related]
43. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
[TBL] [Abstract][Full Text] [Related]
44. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
[TBL] [Abstract][Full Text] [Related]
45. The value of left ventricular global longitudinal strain assessed by three-dimensional strain imaging in the early detection of anthracyclinemediated cardiotoxicity.
Mornoş C; Manolis AJ; Cozma D; Kouremenos N; Zacharopoulou I; Ionac A
Hellenic J Cardiol; 2014; 55(3):235-44. PubMed ID: 24862616
[TBL] [Abstract][Full Text] [Related]
46. Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters.
Díaz-Antón B; Madurga R; Zorita B; Wasniewski S; Moreno-Arciniegas A; López-Melgar B; Ramírez Merino N; Martín-Asenjo R; Barrio P; Amado Escañuela MG; Solís J; Parra Jiménez FJ; Ciruelos E; Castellano JM; Fernández-Friera L
ESC Heart Fail; 2022 Apr; 9(2):1127-1137. PubMed ID: 35106939
[TBL] [Abstract][Full Text] [Related]
47. Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
Kotwinski P; Smith G; Cooper J; Sanders J; Ma L; Teis A; Kotwinski D; Mythen M; Pennell DJ; Jones A; Montgomery H;
PLoS One; 2016; 11(12):e0165262. PubMed ID: 27911951
[TBL] [Abstract][Full Text] [Related]
48. Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity.
Charbonnel C; Convers-Domart R; Rigaudeau S; Taksin AL; Baron N; Lambert J; Ghez S; Georges JL; Farhat H; Lambert J; Rousselot P; Livarek B
Eur Heart J Cardiovasc Imaging; 2017 Apr; 18(4):392-401. PubMed ID: 28064155
[TBL] [Abstract][Full Text] [Related]
49. Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status.
Horacek JM; Vasatova M; Pudil R; Tichy M; Zak P; Jakl M; Jebavy L; Maly J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Dec; 158(4):511-7. PubMed ID: 24457832
[TBL] [Abstract][Full Text] [Related]
50. Long-term cardiac effects of treatment for childhood leukemia.
Urbanova D; Urban L; Simkova I; Danova K; Mikuskova E; Mladosievicova B
Neoplasma; 2010; 57(2):179-83. PubMed ID: 20099983
[TBL] [Abstract][Full Text] [Related]
51. Minimizing cardiac toxicity in children with acute myeloid leukemia.
Narayan HK; Getz KD; Leger KJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355
[TBL] [Abstract][Full Text] [Related]
52. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
[TBL] [Abstract][Full Text] [Related]
53. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
[TBL] [Abstract][Full Text] [Related]
54. Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?
Malik A; Jeyaraj PA; Calton R; Uppal B; Negi P; Shankar A; Patil J; Mahajan MK
Asian Pac J Cancer Prev; 2016; 17(4):2301-5. PubMed ID: 27221934
[TBL] [Abstract][Full Text] [Related]
55. Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia. Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zürich, Switzerland, between 1990 and 1996.
Dazzi H; Kaufmann K; Follath F
Ann Oncol; 2001 Jul; 12(7):963-6. PubMed ID: 11521803
[TBL] [Abstract][Full Text] [Related]
56. Elevations in High-Sensitive Cardiac Troponin T and N-Terminal Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict the Development of Anthracycline-Induced Cardiomyopathy.
Bisoc A; Ciurescu D; Rădoi M; Tântu MM; Rogozea L; Sweidan AJ; Bota DA
Am J Ther; 2020; 27(2):e142-e150. PubMed ID: 30648987
[TBL] [Abstract][Full Text] [Related]
57. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
Matos E; Jug B; Blagus R; Zakotnik B
Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
[TBL] [Abstract][Full Text] [Related]
58. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
[TBL] [Abstract][Full Text] [Related]
59. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
[TBL] [Abstract][Full Text] [Related]
60. Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy.
Leger KJ; Leonard D; Nielson D; de Lemos JA; Mammen PP; Winick NJ
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28377429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
